| anaphylaxis

Auvi-Q vs Neffy

Side-by-side clinical, coverage, and cost comparison for anaphylaxis.

Deep comparison between: Auvi-Q vs Neffy with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsNeffy has a higher rate of injection site reactions vs Auvi-Q based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Neffy but not Auvi-Q, including UnitedHealthcare

Category

Auvi-Q

Neffy

At A Glance

RouteIM or SC injection

ClassSympathomimetic catecholamine

RouteNasal spray

FrequencyAs needed

ClassSympathomimetic catecholamine

Indications

anaphylaxis
Immediate hypersensitivity

anaphylaxis

Dosing

anaphylaxis, Immediate hypersensitivity Weight-based single dose IM or SC into anterolateral thigh: 0.3 mg (>=30 kg), 0.15 mg (15 to <30 kg), 0.1 mg (7.5 to <15 kg); a second dose may be given with a new autoinjector starting 5 minutes after the first dose.

anaphylaxis (>=30 kg) One spray of neffy 2 mg intranasally; if symptoms do not improve or worsen, a second dose may be administered in the same nostril starting 5 minutes after the first dose.

anaphylaxis (15 kg to <30 kg) One spray of neffy 1 mg intranasally; if symptoms do not improve or worsen, a second dose may be administered in the same nostril starting 5 minutes after the first dose.

Contraindications

—

Drug Interactions

680View drug interactions

Adverse Reactions

Serious Injection-related complications, serious infections at the injection site, risks associated with use in certain coexisting conditions, allergic reactions associated with sulfite

Postmarketing Angina, arrhythmias, cerebral hemorrhage, hypertension, palpitations, tachycardia, nausea, vomiting, Clostridial infections, transient hyperglycemia, dizziness, tremor, headache, anxiety, restlessness, respiratory difficulties, necrotizing fasciitis, myonecrosis

Most common (>=2%) Nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, feeling jittery, abdominal pain, tremor, nasal pruritus, sneezing, gingival pain, hypoesthesia oral, nasal congestion

Postmarketing Angina, arrhythmias (including fatal ventricular fibrillation), cerebral hemorrhage, hypertension, pallor, palpitations, tachyarrhythmia, tachycardia, vasoconstriction, ventricular ectopy, stress cardiomyopathy, transient hyperglycemia, sweating, disorientation, impaired memory, panic, psychomotor agitation, anxiety, apprehensiveness, restlessness, respiratory difficulties

Pharmacology

Epinephrine acts on both alpha and beta-adrenergic receptors: alpha-receptor activation lessens vasodilation and increased vascular permeability during anaphylaxis, while beta-receptor activation causes bronchial smooth muscle relaxation and alleviates bronchospasm, pruritus, urticaria, and angioedema.

Epinephrine acts on alpha-adrenergic receptors to reduce vasodilation and increased vascular permeability and on beta-adrenergic receptors to relax bronchial smooth muscle, thereby alleviating anaphylaxis symptoms including hypotension, bronchospasm, pruritus, urticaria, and angioedema.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Auvi-Q